File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/mp.15314
- Scopus: eid_2-s2.0-85119175748
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Multi‐contrast four‐dimensional magnetic resonance imaging (MC‐4D‐MRI): Development and initial evaluation in liver tumor patients
Title | Multi‐contrast four‐dimensional magnetic resonance imaging (MC‐4D‐MRI): Development and initial evaluation in liver tumor patients |
---|---|
Authors | |
Keywords | 4D-MRI 5D-MRI MR-guided radiotherapy multi-contrast MRI tumor-enhanced contrast |
Issue Date | 15-Dec-2021 |
Publisher | BioMed Central |
Citation | BMC Medical Physics, 2021, v. 48, n. 12, p. 7984-7997 How to Cite? |
Abstract | PurposeTo develop a novel multi-contrast four-dimensional magnetic resonance imaging (MC-4D-MRI) technique that expands single image contrast 4D-MRI to a spectrum of native and synthetic image contrasts and to evaluate its feasibility in liver tumor patients. Methods and materialsThe MC-4D-MRI technique integrates multi-parametric MRI fusion, 4D-MRI, and deformable image registration (DIR) techniques. The fusion technique consists of native MRI as input, image pre-processing, fusion algorithm, adaptation, and fused multi-contrast MRI as output. Four-dimensional deformation vector fields (4D-DVF) were generated from an original T2/T1-w 4D-MRI by deforming end-of-inhalation (EOI) to nine other phase volumes via DIR. The 4D-DVF were applied to multi-contrast MRI to generate a spectrum of 4D-MRI in different image contrasts. The MC-4D-MRI technique was evaluated in five liver tumor patients on tumor contrast-to-noise ratio (CNR), internal target volume (ITV) contouring consistency, diaphragm motion range, and tumor motion trajectory; and in digital anthropomorphic phantoms on 4D-DIR introduced errors in tumor motion range, centroid location, extent, and volume. ResultsMC-4D-MRI consisting of 4D-MRIs in native image contrasts (T1-w, T2-w, and T2/T1-w) and synthetic image contrasts, such as tumor-enhanced contrast (TEC) were generated in five liver tumor patients. Patient tumor CNR increased from 2.6 ± 1.8 in the T2/T1-w MRI, to -4.4 ± 2.4, 6.6 ± 3.0, and 9.6 ± 3.9 in the T1-w, T2-w, and TEC MRI, respectively. Patient ITV inter-observer mean Dice similarity coefficient (mDSC) increased from 0.65 ± 0.10 in the original T2/T1-w 4D-MRI, to 0.76 ± 0.14, 0.77 ± 0.12, and 0.86 ± 0.05 in the T1-w, T2-w, and TEC 4D-MRI, respectively. Patient diaphragm motion range absolute differences between the three new 4D-MRIs and original T2/T1-w 4D-MRI were 1.2 ± 1.3, 0.3 ± 0.7, and 0.5 ± 0.5 mm, respectively. Patient tumor displacement phase-averaged absolute differences between the three 4D-MRIs and the original 4D-MRI were 0.72 ± 0.33, 0.62 ± 0.54, and 0.74 ± 0.43 mm in the superior-inferior (SI) direction, and 0.59 ± 0.36, 0.51 ± 0.30, and 0.50 ± 0.24 mm in the anterior-posterior (AP) direction, respectively. In the digital phantoms, phase-averaged absolute tumor centroid shift caused by the 4D-DIR were at or below 0.5 mm in SI, AP, and left-right (LR) directions. ConclusionWe developed an MC-4D-MRI technique capable of expanding single image contrast 4D-MRI along a new dimension of image contrast. Initial evaluations in liver tumor patients showed enhancements in image contrast variety, tumor contrast, and ITV contouring consistencies using MC-4D-MRI. The technique might offer new perspectives on the image contrast of MRI and 4D-MRI in MR-guided radiotherapy. |
Persistent Identifier | http://hdl.handle.net/10722/344060 |
ISSN |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Lei | - |
dc.contributor.author | Yin, Fang‐Fang | - |
dc.contributor.author | Li, Tian | - |
dc.contributor.author | Teng, Xinzhi | - |
dc.contributor.author | Xiao, Haonan | - |
dc.contributor.author | Harris, Wendy | - |
dc.contributor.author | Ren, Lei | - |
dc.contributor.author | Kong, FS | - |
dc.contributor.author | Ge, Hong | - |
dc.contributor.author | Mao, Ronghu | - |
dc.contributor.author | Cai, Jing | - |
dc.date.accessioned | 2024-06-27T01:07:03Z | - |
dc.date.available | 2024-06-27T01:07:03Z | - |
dc.date.issued | 2021-12-15 | - |
dc.identifier.citation | BMC Medical Physics, 2021, v. 48, n. 12, p. 7984-7997 | - |
dc.identifier.issn | 1756-6649 | - |
dc.identifier.uri | http://hdl.handle.net/10722/344060 | - |
dc.description.abstract | <h3>Purpose</h3><p>To develop a novel multi-contrast four-dimensional magnetic resonance imaging (MC-4D-MRI) technique that expands single image contrast 4D-MRI to a spectrum of native and synthetic image contrasts and to evaluate its feasibility in liver tumor patients.</p><h3>Methods and materials</h3><p>The MC-4D-MRI technique integrates multi-parametric MRI fusion, 4D-MRI, and deformable image registration (DIR) techniques. The fusion technique consists of native MRI as input, image pre-processing, fusion algorithm, adaptation, and fused multi-contrast MRI as output. Four-dimensional deformation vector fields (4D-DVF) were generated from an original T2/T1-w 4D-MRI by deforming end-of-inhalation (EOI) to nine other phase volumes via DIR. The 4D-DVF were applied to multi-contrast MRI to generate a spectrum of 4D-MRI in different image contrasts. The MC-4D-MRI technique was evaluated in five liver tumor patients on tumor contrast-to-noise ratio (CNR), internal target volume (ITV) contouring consistency, diaphragm motion range, and tumor motion trajectory; and in digital anthropomorphic phantoms on 4D-DIR introduced errors in tumor motion range, centroid location, extent, and volume.</p><h3>Results</h3><p>MC-4D-MRI consisting of 4D-MRIs in native image contrasts (T1-w, T2-w, and T2/T1-w) and synthetic image contrasts, such as tumor-enhanced contrast (TEC) were generated in five liver tumor patients. Patient tumor CNR increased from 2.6 ± 1.8 in the T2/T1-w MRI, to -4.4 ± 2.4, 6.6 ± 3.0, and 9.6 ± 3.9 in the T1-w, T2-w, and TEC MRI, respectively. Patient ITV inter-observer mean Dice similarity coefficient (mDSC) increased from 0.65 ± 0.10 in the original T2/T1-w 4D-MRI, to 0.76 ± 0.14, 0.77 ± 0.12, and 0.86 ± 0.05 in the T1-w, T2-w, and TEC 4D-MRI, respectively. Patient diaphragm motion range absolute differences between the three new 4D-MRIs and original T2/T1-w 4D-MRI were 1.2 ± 1.3, 0.3 ± 0.7, and 0.5 ± 0.5 mm, respectively. Patient tumor displacement phase-averaged absolute differences between the three 4D-MRIs and the original 4D-MRI were 0.72 ± 0.33, 0.62 ± 0.54, and 0.74 ± 0.43 mm in the superior-inferior (SI) direction, and 0.59 ± 0.36, 0.51 ± 0.30, and 0.50 ± 0.24 mm in the anterior-posterior (AP) direction, respectively. In the digital phantoms, phase-averaged absolute tumor centroid shift caused by the 4D-DIR were at or below 0.5 mm in SI, AP, and left-right (LR) directions.</p><h3>Conclusion</h3><p>We developed an MC-4D-MRI technique capable of expanding single image contrast 4D-MRI along a new dimension of image contrast. Initial evaluations in liver tumor patients showed enhancements in image contrast variety, tumor contrast, and ITV contouring consistencies using MC-4D-MRI. The technique might offer new perspectives on the image contrast of MRI and 4D-MRI in MR-guided radiotherapy.</p> | - |
dc.language | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.ispartof | BMC Medical Physics | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | 4D-MRI | - |
dc.subject | 5D-MRI | - |
dc.subject | MR-guided radiotherapy | - |
dc.subject | multi-contrast MRI | - |
dc.subject | tumor-enhanced contrast | - |
dc.title | Multi‐contrast four‐dimensional magnetic resonance imaging (MC‐4D‐MRI): Development and initial evaluation in liver tumor patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/mp.15314 | - |
dc.identifier.scopus | eid_2-s2.0-85119175748 | - |
dc.identifier.volume | 48 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 7984 | - |
dc.identifier.epage | 7997 | - |
dc.identifier.eissn | 1756-6649 | - |
dc.identifier.issnl | 1756-6649 | - |